James L. Freddo

Phase I Trial of the Oral Antiangiogenesis Agent AG-013736 in Patients With Advanced Solid Tumors: Pharmacokinetic and Clinical Results

Hope S. Rugo, Roy S. Herbst, Glenn Liu et al. · Journal of Clinical Oncology · 2005 · 485 citations · Full text

Pharmacy, Oncology, Pharmacology +17

Axitinib treatment in patients with cytokine-refractory metastatic renal-cell cancer: a phase II study

Olivier Rixe, Ronald M. Bukowski, M. Dror Michaelson et al. · The Lancet Oncology · 2007 · 436 citations

Medicine, Oncology, Pharmacology +14

Cytoreductive Surgery in Advanced Epithelial Cancer of the Ovary: The Impact of Aortic and Pelvic Lymphadenectomy

Nick M. Spirtos, Gary M. Gross, James L. Freddo et al. · Gynecologic Oncology · 1995 · 103 citations

Medicine, Oncology, Surgery +16

Profiles of women age 30-39 and age less than 30 with epithelial ovarian cancer.

Steven C. Plaxe, Patricia S. Braly, James L. Freddo et al. · PubMed · 1993 · 66 citations

Medicine, Gynecology, Oncology +17

Randomised clinical trial: anti-viral activity of ANA773, an oral inducer of endogenous interferons acting via TLR7, in chronic HCV

Jean‐François Bergmann, Joep de Bruijne, Daphne M. Hotho et al. · Alimentary Pharmacology & Therapeutics · 2011 · 52 citations

Medicine, Infectious Diseases, Pharmacology +17